Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia

ClinicalTrials.gov ID: NCT00645398

Public ClinicalTrials.gov record NCT00645398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 13-week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of pregabalin versus placebo for the symptomatic relief of pain associated with fibromyalgia. If this objective is met, then the second objective will be to evaluate the efficacy and safety of pregabalin versus placebo for the management of fibromyalgia (pain, patient global assessment, and functional status). Additionally, the study will evaluate the efficacy of pregabalin versus placebo to improve sleep, fatigue, and mood disturbance associated with fibromyalgia.

Study identification

NCT ID
NCT00645398
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
751 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2004 (Type not available)
Primary completion
Not listed
Completion
Jun 2005 (Actual)
Last update posted
Jan 25, 2021

2004 – 2005

United States locations

U.S. sites
102
U.S. states
30
U.S. cities
84
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35294 —
Pfizer Investigational Site Huntsville Alabama 35801 —
Pfizer Investigational Site Paradise Valley Arizona 85253 —
Pfizer Investigational Site Phoenix Arizona 85023 —
Pfizer Investigational Site Phoenix Arizona 85032 —
Pfizer Investigational Site Scottsdale Arizona 85254 —
Pfizer Investigational Site Hot Springs Arkansas 71913 —
Pfizer Investigational Site Little Rock Arkansas 72205 —
Pfizer Investigational Site Beverly Hills California 90211 —
Pfizer Investigational Site Long Beach California 90806 —
Pfizer Investigational Site Los Alamitos California 90720 —
Pfizer Investigational Site Newport Beach California 92660 —
Pfizer Investigational Site Northridge California 91324-4625 —
Pfizer Investigational Site Northridge California 91335 —
Pfizer Investigational Site Pismo Beach California 93449 —
Pfizer Investigational Site Redondo Beach California 90277 —
Pfizer Investigational Site Riverside California 92501 —
Pfizer Investigational Site Riverside California 92506 —
Pfizer Investigational Site Walnut Creek California 94598 —
Pfizer Investigational Site Whittier California 90601 —
Pfizer Investigational Site Danbury Connecticut 06810 —
Pfizer Investigational Site New Milford Connecticut 06776 —
Pfizer Investigational Site Stratford Connecticut 06615 —
Pfizer Investigational Site Clearwater Florida 33761 —
Pfizer Investigational Site Miami Florida 33173 —
Pfizer Investigational Site Ocala Florida 34474 —
Pfizer Investigational Site Palm Beach Gardens Florida 33410 —
Pfizer Investigational Site Plantation Florida 33317 —
Pfizer Investigational Site Plantation Florida 33324 —
Pfizer Investigational Site St. Petersburg Florida 33703 —
Pfizer Investigational Site St. Petersburg Florida 33709 —
Pfizer Investigational Site St. Petersburg Florida 33710 —
Pfizer Investigational Site Sunrise Florida 33351-6637 —
Pfizer Investigational Site West Palm Beach Florida 33409 —
Pfizer Investigational Site Atlanta Georgia 30328 —
Pfizer Investigational Site Atlanta Georgia 30342 —
Pfizer Investigational Site Decatur Georgia 30033-5930 —
Pfizer Investigational Site Boise Idaho 83704 —
Pfizer Investigational Site Chicago Illinois 60610 —
Pfizer Investigational Site Maywood Illinois 60153 —
Pfizer Investigational Site Oak Brook Illinois 60523 —
Pfizer Investigational Site Peoria Illinois 61614 —
Pfizer Investigational Site Kansas City Kansas 66160 —
Pfizer Investigational Site Overland Park Kansas 66210 —
Pfizer Investigational Site Overland Park Kansas 66215 —
Pfizer Investigational Site Madisonville Kentucky 42431 —
Pfizer Investigational Site New Orleans Louisiana 70114 —
Pfizer Investigational Site Newton Massachusetts 02462 —
Pfizer Investigational Site East Lansing Michigan 48823 —
Pfizer Investigational Site Kalamazoo Michigan 49009 —
Pfizer Investigational Site Lansing Michigan 48917 —
Pfizer Investigational Site Kansas City Missouri 64114 —
Pfizer Investigational Site Lebanon New Hampshire 03766 —
Pfizer Investigational Site Princeton New Jersey 08540 —
Pfizer Investigational Site Albany New York 12205 —
Pfizer Investigational Site New York New York 10003 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site Charlotte North Carolina 28210 —
Pfizer Investigational Site Wilmington North Carolina 28401 —
Pfizer Investigational Site Wilmington North Carolina 28403 —
Pfizer Investigational Site Winston-Salem North Carolina 27103 —
Pfizer Investigational Site Cincinnati Ohio 45219 —
Pfizer Investigational Site Columbus Ohio 43124 —
Pfizer Investigational Site Columbus Ohio 43212 —
Pfizer Investigational Site Mogadore Ohio 44260 —
Pfizer Investigational Site Toledo Ohio 43623 —
Pfizer Investigational Site Oklahoma City Oklahoma 73109 —
Pfizer Investigational Site Eugene Oregon 97401 —
Pfizer Investigational Site Medford Oregon 97504 —
Pfizer Investigational Site Portland Oregon 97201 —
Pfizer Investigational Site Altoona Pennsylvania 16601 —
Pfizer Investigational Site Altoona Pennsylvania 16602 —
Pfizer Investigational Site Duncansville Pennsylvania 16635 —
Pfizer Investigational Site Johnstown Pennsylvania 15904 —
Pfizer Investigational Site Mechanicsburg Pennsylvania 17055 —
Pfizer Investigational Site Philadelphia Pennsylvania 19115 —
Pfizer Investigational Site Philadelphia Pennsylvania 19146 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15213 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15218 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15224 —
Pfizer Investigational Site Pottstown Pennsylvania 19610 —
Pfizer Investigational Site West Reading Pennsylvania 19611-1124 —
Pfizer Investigational Site Wyomissing Pennsylvania 19610 —
Pfizer Investigational Site Anderson South Carolina 29621 —
Pfizer Investigational Site Charleston South Carolina 29406 —
Pfizer Investigational Site Greer South Carolina 29651 —
Pfizer Investigational Site Memphis Tennessee 38104 —
Pfizer Investigational Site Memphis Tennessee 38119 —
Pfizer Investigational Site Nashville Tennessee 37203 —
Pfizer Investigational Site Austin Texas 78705 —
Pfizer Investigational Site Dallas Texas 75246 —
Pfizer Investigational Site Lubbock Texas 79424 —
Pfizer Investigational Site Richardson Texas 75080 —
Pfizer Investigational Site San Antonio Texas 78229-4540 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site Salt Lake City Utah 84102 —
Pfizer Investigational Site Woodstock Vermont 05091-0437 —
Pfizer Investigational Site Woodstock Vermont 05091 —
Pfizer Investigational Site Virginia Beach Virginia 23454 —
Pfizer Investigational Site Seattle Washington 98104 —
Pfizer Investigational Site Seattle Washington 98122 —
Pfizer Investigational Site Yakima Washington 98902 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00645398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 25, 2021 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00645398 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →